Other languages Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Market Closed - London S.E. Other stock markets 11:35:02 2024-05-03 am EDT			5-day change	1st Jan Change
1.565 ^GBX	-0.13%		-5.15%	-31.96%

Apr. 25	Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 29	Hemogenyx Pharmaceuticals raises money for leukaemia treatment	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	Apr. 25
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	Feb. 29
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	Feb. 29
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	Feb. 16
Hemogenyx shares rise on potential for CBR to treat brain diseases	Feb. 16
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	Feb. 16
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	Feb. 14
Hemogenyx says CBR can be used intranasally to treat viral infections	Feb. 14
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	Feb. 09
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	Feb. 09
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	Feb. 09
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	Feb. 02
Hemogenyx hails US patent application progress	Feb. 02
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	Feb. 02
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	Jan. 16
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	Jan. 16
Hemogenyx Pharmaceuticals completes process qualification run	Jan. 08
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	Jan. 08
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	Jan. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Other languages

Filters